Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Xenikos B.V. logo — Developing new, innovative immunotherapy medicines that rese...

Xenikos B.V.

Developing new, innovative immunotherapy medicines that reset the immune system

Founded 2009 The Netherlands The Netherlands 1 employees Grant Total: $78.00M Biotechnology, Health and Wellness +1

General Information

Company Name Xenikos B.V.
Founded Year 2009
Location The Netherlands The Netherlands
Founders / Decision Makers
Team member Team member Team member
Employees 1
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Grant
Business Model B2B, B2B2B, B2B2C
Revenue Model Product Sales, Licensing, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with Xenikos B.V.. To contact Xenikos B.V., visit xenikos.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Xenikos B.V. compare?

A PDF of Xenikos B.V. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Xenikos B.V. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Xenikos B.V.

Xenikos B.V., founded in 2009 and headquartered in The Netherlands, is a clinical-stage biotechnology company noted for its slogan, "Developing new, innovative immunotherapy medicines that reset the immune system." The company is positioned at the intersection of biotechnology, health and wellness, and life sciences.

Its lead product candidate, T-Guard®, is at the forefront of the company's efforts, currently in Phase 3 development targeting steroid-refractory acute graft-versus-host disease (SR-aGVHD). The potential applications of T-Guard span across various immune conditions, including transplant-related rejection and severe autoimmune diseases, demonstrating the versatility and promise of its mechanism.

Xenikos's recent financial backing includes a €2.50M grant from the European Innovation Council in December 2022. This investment underscores investor confidence in Xenikos's innovative approach to resetting immune systems in critical health scenarios.

Business keywords: Immunotherapy, Clinical-stage, Graft-versus-host disease, Steroid-refractory conditions, Transplant rejection, Antibody-based therapy, Autoimmune diseases, Solid-organ rejection, Innovative medicine development, Immune system reset, Drug development, Clinical development, Biopharmacy, Therapeutic innovation

Services & Products

Development of Immunotherapy Medicines
Clinical Trials Management
Research on Immune System Disorders

Target Customers

Patients with Immune System Disorders Healthcare Professionals in Transplant Medicine Research Institutions

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €2.50M 1
European Innovation Council
European Innovation Council
19 Dec 2022
Convertible Note €40.00M 5
RA Capital Management Oost NL Sanquin
RA Capital Management, Oost NL +3
08 Sep 2021
Series B $30.00M 2
RA Capital Management
RA Capital Management, Medicxi
15 May 2018
Debt Financing €1.90M 1
Agentschap NL
19 Jun 2012
Series A €3.60M 1
Innovation & Investment Fund Gelderland
19 Jun 2012

Xenikos B.V. Alternatives & Competitors

View All Alternatives
Xenikos B.V. vs
Enlivex Therapeutics (Nasdaq: ENLV)
Enlivex Therapeutics (Nasdaq: ENLV) Israel

Immune rebalancing

Post-IPO Equity
41 employees
Biotechnology, Health Care
Xenikos B.V. vs
Tridek-One
Tridek-One France

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

Venture round
12 employees
Biotechnology, Health Care
Xenikos B.V. vs
Taiga Biotechnologies
Taiga Biotechnologies United States

Taiga Biotechnologies is a clinical stage biotechnology company focused on harnessing the power of t...

Seed
1 employees
Biotechnology, Health and Wellness
Also compare with: Xenikos B.V. vs SAB BIO SAB BIO View all alternatives

FAQ About Xenikos B.V.

Developing new, innovative immunotherapy medicines that reset the immune system
Xenikos B.V. was founded in 2009.
Xenikos B.V. is headquartered in The Netherlands.
Xenikos B.V. operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on Immunotherapy, Clinical-stage, Graft-versus-host disease and Steroid-refractory conditions. Its customers include Patients with Immune System Disorders, Healthcare Professionals in Transplant Medicine and Research Institutions.
Xenikos B.V. has a B2B, B2B2B and B2B2C business model. Its revenue comes from Product Sales, Licensing and Value Based Pricing.
Xenikos B.V. has approximately 1 employees.
Xenikos B.V. has completed 5 funding rounds, raising a total of $78.00M. The latest funding stage is Grant.
Xenikos B.V. offers: Development of Immunotherapy Medicines, Clinical Trials Management, Research on Immune System Disorders.
Top alternatives and competitors to Xenikos B.V. include Enlivex Therapeutics (Nasdaq: ENLV), Tridek-One, Taiga Biotechnologies, Magenta Therapeutics, Asylia Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xenikos B.V. and Enlivex Therapeutics (Nasdaq: ENLV) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Xenikos B.V., https://bouncewatch.com/company/xenikos-bv, updated 11 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout